quinoxalines has been researched along with naltrexone in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pinnock, RD | 1 |
| Intengan, HD; Smyth, DD | 2 |
| Cosentino, M; De Ponti, F; Frigo, G; Giaroni, C; Lecchini, S; Marino, F; Senaldi, A; Somaini, L | 1 |
| Sareen, D | 1 |
| Kong, LL; Yu, LC | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Bartlett, SE; Holgate, J; Richards, JK; Simms, JA; Steensland, P | 1 |
| Tyndale, R | 1 |
| Ceballos-Reyes, G; Granados-Soto, V; Jiménez-Andrade, GY; Reyes-García, G; Sereno, G; Vidal-Cantú, GC | 1 |
| Kuehn, BM | 1 |
| Arttamangkul, S; Birdsong, WT; Virk, MS; Williams, JT | 1 |
| Hentges, ST; Pennock, RL | 1 |
| Dicken, MS; Hentges, ST; Tooker, RE | 1 |
| Cervantes-Durán, C; Espinosa de los Monteros-Zuñiga, A; Godínez-Chaparro, B; Izquierdo, T; Lozada, MC | 1 |
| Brody, A; Courtney, KE; Ghahremani, DG; London, ED; Miotto, K; Ray, LA | 2 |
| Bujarski, S; Ray, LA | 1 |
| Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA | 1 |
| Hussar, DA | 1 |
1 review(s) available for quinoxalines and naltrexone
| Article | Year |
|---|---|
Neuroprotective agents in acute ischemic stroke.
Topics: Acute Disease; Adult; Aged; Animals; Antioxidants; Calcium Channel Blockers; Chlormethiazole; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Forecasting; GABA Modulators; Guanidines; Humans; Imidazoles; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Pipecolic Acids; Piperidines; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Reperfusion Injury; Stroke; Thiazoles | 2002 |
3 trial(s) available for quinoxalines and naltrexone
| Article | Year |
|---|---|
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
Topics: Adult; Alcohol Drinking; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult | 2014 |
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
Topics: Adult; Alcoholism; Benzazepines; Brain; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2015 |
Negative affect is associated with alcohol, but not cigarette use in heavy drinking smokers.
Topics: Adult; Affect; Alcohol-Related Disorders; Benzazepines; Comorbidity; Craving; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult | 2014 |
16 other study(ies) available for quinoxalines and naltrexone
| Article | Year |
|---|---|
Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphé nucleus in vitro.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Animals; Benzofurans; Bicuculline; Bombesin; Cholecystokinin; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Evoked Potentials; Glutamates; Glutamic Acid; In Vitro Techniques; Kynurenic Acid; N-Methylaspartate; Naloxone; Naltrexone; Neurons; Picrotoxin; Prazosin; Pyrrolidines; Quinoxalines; Raphe Nuclei; Rats; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Serotonin; Synapses; Tetrodotoxin | 1992 |
Clonidine-induced increase in osmolar clearance and free water clearance via activation of two distinct alpha 2-adrenoceptor sites.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Clonidine; Male; Naltrexone; Osmolar Concentration; Prazosin; Quinoxalines; Rats; Rats, Sprague-Dawley; Water | 1996 |
Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance.
Topics: Adrenergic alpha-Agonists; Animals; Body Water; Brimonidine Tartrate; Guanfacine; Idazoxan; Kidney; Male; Naltrexone; Prazosin; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 1997 |
Modulation of enteric cholinergic neurons by hetero- and autoreceptors: cooperation among inhibitory inputs.
Topics: Acetylcholine; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cholinergic Fibers; Colon; Denervation; Guinea Pigs; Motor Neurons; Naltrexone; Norepinephrine; Peristalsis; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Opioid; Sympathetic Nervous System | 1999 |
Involvement of mu- and delta-opioid receptors in the antinociceptive effects induced by AMPA receptor antagonist in the spinal cord of rats.
Topics: Analgesics; Animals; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Pain Measurement; Physical Stimulation; Quinoxalines; Rats; Rats, Wistar; Reaction Time; Receptors, AMPA; Receptors, Opioid, delta; Receptors, Opioid, mu; Spinal Cord; Wakefulness | 2006 |
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
Topics: Animals; Appetite; Behavior, Addictive; Behavior, Animal; Benzazepines; Ethanol; Male; Naltrexone; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Sensitivity and Specificity; Sucrose; Varenicline; Water | 2007 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline | 2008 |
Pyritinol reduces nociception and oxidative stress in diabetic rats.
Topics: Analgesics; Animals; Diabetes Mellitus, Experimental; Female; Indomethacin; Naltrexone; Oxadiazoles; Oxidative Stress; Pyrithioxin; Quinoxalines; Rats; Rats, Wistar; Streptozocin | 2008 |
Findings on alcohol dependence point to promising avenues for targeted therapies.
Topics: Alcoholism; Animals; Benzazepines; Humans; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Nicotinic Agonists; Pharmacogenetics; Pyridines; Quinoxalines; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Stress, Psychological; Triazoles; Varenicline | 2009 |
Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Biophysics; Brain; Brimonidine Tartrate; Buprenorphine; Dose-Response Relationship, Drug; Electric Stimulation; Enkephalin, Methionine; In Vitro Techniques; Male; Membrane Potentials; Mice; Mice, Transgenic; Naltrexone; Narcotic Antagonists; Narcotics; Neural Inhibition; Neurons; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Yohimbine | 2009 |
Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons.
Topics: Analgesics; Analgesics, Opioid; Analysis of Variance; Animals; Benzeneacetamides; Dizocilpine Maleate; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Gene Expression; Hypothalamus; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Luminescent Proteins; Membrane Potentials; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naltrexone; Narcotic Antagonists; Neural Inhibition; Neurons; Patch-Clamp Techniques; Peptide Fragments; Pro-Opiomelanocortin; Pyrrolidines; Quinoxalines; Receptors, Opioid; Somatostatin; Synapses | 2011 |
Regulation of GABA and glutamate release from proopiomelanocortin neuron terminals in intact hypothalamic networks.
Topics: Adrenocorticotropic Hormone; Analgesics, Opioid; Animals; Channelrhodopsins; Excitatory Postsynaptic Potentials; Female; gamma-Aminobutyric Acid; Glutamic Acid; Hypothalamus; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Light; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naltrexone; Narcotic Antagonists; Nerve Net; Neurons; Neurotransmitter Agents; Patch-Clamp Techniques; Peptides; Presynaptic Terminals; Pro-Opiomelanocortin; Quinoxalines | 2012 |
Mechanisms underlying the antinociceptive effect of mangiferin in the formalin test.
Topics: Analgesics; Animals; Capsaicin; Formaldehyde; Glyburide; Male; Naloxone; Naltrexone; NG-Nitroarginine Methyl Ester; Nociception; Quinoxalines; Rats; Rats, Wistar; Serotonin; Xanthones | 2013 |
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.
Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline | 2014 |
New Drugs 2018, part 1.
Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration | 2018 |